XL01126
Based on 1 publication(s) in Google Scholar
XL01126 is a blood-brain barrier-permeable, selective LRRK2 PROTAC degrader (DC50: 14 nM (G2019S LRRK2) and 32 nM (WT LRRK2)). XL01126 forms a positively cooperative ternary complex with VHL E3 ubiquitin ligase and LRRK2, mediating the polyubiquitination and proteasomal degradation of LRRK2. XL01126 induces Mitophagy. XL01126 is applicable to research related to Parkinson's disease.
(Pink: LRRK2 ligand (HY-13488); Blue: VHL ligand (HY-150802); Black: linker).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.90%
- CAS. Nr.: 3011029-58-3
- Formel: C50H64ClFN10O6S2
- Molecular Weight:1019.69
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) XL01126
MoreAlle PROTACs Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
VHL |
In Vitro
XL01126 (0-10000 nM; 4 h) potently degrades wild-type (WT) LRRK2 (DC50 = 32 nM, Dmax = 82%) and the LRRK2G2019S mutant (DC50 = 14 nM, Dmax = 90%) after a 4-h treatment in MEFs, while it also potently inhibits Rab10 phosphorylation (EC50 = 54 nM for WT, EC50 = 15 nM for G2019S)[1].
XL01126 (0-3000 nM; 4 h) potently degrades LRRK2 in mouse bone marrow-derived macrophages (BMDM) after 4 hours, with a DC50 of 55 nM and a Dmax of 83%[1].
XL01126 forms a positively cooperative ternary complex with VHL and LRRK2 in permeabilized HEK293 cells (α = 5.7), a property that supports its potent LRRK2 degradation activity[1].
XL01126 (10-100 nM; 24 h) induces mitophagy in immortalized Mito-QC mouse embryonic fibroblasts (MEFs) in a dose-dependent manner after 24 h of treatment at concentrations of 10, 30, and 100 nM[1].
XL01126 exhibits high stability in mouse plasma and hepatocytes[1].
XL01126 efficiently and selectively degrades LRRK2 in LRRK2R1441C mutant mouse embryonic fibroblasts, bone marrow-derived macrophages, and peripheral blood mononuclear cells, with a DC50 range of 15-72 nM, and forms a positively cooperative ternary complex with VHL and LRRK2[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:wild-type (WT) mouse embryonic fibroblasts (MEFs), G2019S LRRK2 MEFs
-
Concentration:0-10000 nM
-
Incubation Time:4 h
-
Result:Dose-dependently degraded WT LRRK2 with a DC50 of 32 nM and a maximum degradation (Dₘₐₓ) of 82%.
Dose-dependently degraded G2019S LRRK2 with a DC50 of 14 nM and a Dₘₐₓ of 90%.
Dose-dependently inhibited Rab10 phosphorylation, with an EC50 of 54 nM in WT MEFs and 15 nM in G2019S LRRK2 MEFs.
Showed no "hook effect" at concentrations up to 10000 nM.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 | AUClast | AUCinf | F | CL | Vss | MRT |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 5 mg/kg | i.v. | / | / | 1.52 h | 23663 ng·h/mL | 23981 ng·h/mL | / | 0.208 L/h/kg | 0.511 L/kg | 2.45 h |
| Mice[1] | 30 mg/kg | i.p. | 0.25 h | 7700 ng/mL | 5.2 h | 41434 ng·h/mL | 64068 ng·h/mL | 29.2 % | / | / | / |
| Mice[1] | 30 mg/kg | p.o. | 2 h | 3620 ng/mL | 21.9 h | 21337 ng·h/mL | 109271 ng·h/mL | 15 % | / | / | / |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 3011029-58-3
-
Appearance Solid
-
Molecular Weight 1019.69
-
Formel C50H64ClFN10O6S2
-
Color White to off-white
-
SMILES
O=C([C@H]1N(C([C@@H](NC(C2(F)CC2)=O)C(C)(SC[C@@H]3CC[C@@H](CN4CCN(C(C5=CC=C(NC6=NC=C(Cl)C(NC)=N6)C(OC)=C5)=O)CC4)CC3)C)=O)C[C@H](O)C1)NCC7=CC=C(C8=C(C)N=CS8)C=C7
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Lösungsmittel & Löslichkeit
In Vitro:
DMSO : ≥ 100 mg/mL (98.07 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Liu X, et al. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2. Journal of the American Chemical Society. 2022 Sep 21;144(37):16930-16952. [Content Brief]
[2]. Tang X, et al. The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease. Journal of medicinal chemistry. 2023 Feb 23;66(4):2282-2307. [Content Brief]
[3]. Li M, et al. Advancing Strategies for Proteolysis-Targeting Chimera Design. Journal of medicinal chemistry. 2023 Feb 23;66(4):2308-2329. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9807 mL | 4.9035 mL | 9.8069 mL | 24.5173 mL |
| 5 mM | 0.1961 mL | 0.9807 mL | 1.9614 mL | 4.9035 mL | |
| 10 mM | 0.0981 mL | 0.4903 mL | 0.9807 mL | 2.4517 mL | |
| 15 mM | 0.0654 mL | 0.3269 mL | 0.6538 mL | 1.6345 mL | |
| 20 mM | 0.0490 mL | 0.2452 mL | 0.4903 mL | 1.2259 mL | |
| 25 mM | 0.0392 mL | 0.1961 mL | 0.3923 mL | 0.9807 mL | |
| 30 mM | 0.0327 mL | 0.1634 mL | 0.3269 mL | 0.8172 mL | |
| 40 mM | 0.0245 mL | 0.1226 mL | 0.2452 mL | 0.6129 mL | |
| 50 mM | 0.0196 mL | 0.0981 mL | 0.1961 mL | 0.4903 mL | |
| 60 mM | 0.0163 mL | 0.0817 mL | 0.1634 mL | 0.4086 mL | |
| 80 mM | 0.0123 mL | 0.0613 mL | 0.1226 mL | 0.3065 mL |
XL01126 Related Classifications
HY-148030 Related Classifications
Powered by Bioz